Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 23, No 36 (December 20), 2005: pp. 9408-9421
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.01.5594

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwartz, G. K.
Right arrow Articles by Shah, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwartz, G. K.
Right arrow Articles by Shah, M. A.

BIOLOGY OF NEOPLASIA

Targeting the Cell Cycle: A New Approach to Cancer Therapy

Gary K. Schwartz, Manish A. Shah

From the Department of Medicine, Division of Solid Tumor Oncology, Gastrointestinal Oncology Service; and the Laboratory of New Drug Development, Memorial Sloan-Kettering Cancer Center, New York, NY

Address reprint requests to Gary K. Schwartz, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: schwartg{at}mskcc.org

The cell cycle represents a series of tightly integrated events that allow the cell to grow and proliferate. Critical parts of the cell cycle machinery are the cyclin-dependent kinases (CDKs), which, when activated, provide a means for the cell to move from one phase of the cell cycle to the next. The CDKs are regulated positively by cyclins and regulated negatively by naturally occurring CDK inhibitors (CDKIs). Cancer represents a dysregulation of the cell cycle such that cells that overexpress cyclins or do not express the CDKIs continue to undergo unregulated cell growth. The cell cycle also serves to protect the cell from DNA damage. Thus, cell cycle arrest, in fact, represents a survival mechanism that provides the tumor cell the opportunity to repair its own damaged DNA. Thus, abrogation of cell cycle checkpoints, before DNA repair is complete, can activate the apoptotic cascade, leading to cell death. Now in clinical trials are a series of targeted agents that directly inhibit the CDKs, inhibit unrestricted cell growth, and induce growth arrest. Recent attention has also focused on these drugs as inhibitors of transcription. In addition, there are now agents that abrogate the cell cycle checkpoints at critical time points that make the tumor cell susceptible to apoptosis. An understanding of the cell cycle is critical to understanding how best to clinically develop these agents, both as single agents and in combination with chemotherapy.

Supported by National Cancer Institute (Bethesda, MD) Grant No. R01 CA 067819 (G.K.S.), and by the American Society of Clinical Oncology Young Investigator Award 2001 and the Cancer and Leukemia Group B Investigator Award 2001 (M.A.S.).

Authors’ disclosures of potential conflicts of interest are found at the end of this article.




This article has been cited by other articles:


Home page
Cancer Res.Home page
R. P. Singh, M. Gu, and R. Agarwal
Silibinin Inhibits Colorectal Cancer Growth by Inhibiting Tumor Cell Proliferation and Angiogenesis
Cancer Res., March 15, 2008; 68(6): 2043 - 2050.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
L. Fini, E. Hotchkiss, V. Fogliano, G. Graziani, M. Romano, E. B. De Vol, H. Qin, M. Selgrad, C.R. Boland, and L. Ricciardiello
Chemopreventive properties of pinoresinol-rich olive oil involve a selective activation of the ATM-p53 cascade in colon cancer cell lines
Carcinogenesis, January 1, 2008; 29(1): 139 - 146.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
A. Melck, H. Masoudi, O. L. Griffith, A. Rajput, G. Wilkins, S. Bugis, S. J. M. Jones, and S. M. Wiseman
Cell Cycle Regulators Show Diagnostic and Prognostic Utility for Differentiated Thyroid Cancer.
Ann. Surg. Oncol., December 1, 2007; 14(12): 3403 - 3411.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. D. Gross, J. O. Boyle, B. Du, V. D. Kekatpure, A. Lantowski, H. T. Thaler, B. B. Weksler, K. Subbaramaiah, and A. J. Dannenberg
Inhibition of Jun NH2-Terminal Kinases Suppresses the Growth of Experimental Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., October 1, 2007; 13(19): 5910 - 5917.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. Wang, M. R. Spitz, H. Yang, C. Lu, D. J. Stewart, and X. Wu
Genetic Variants in Cell Cycle Control Pathway Confer Susceptibility to Lung Cancer
Clin. Cancer Res., October 1, 2007; 13(19): 5974 - 5981.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. B. Stevens, G. Liu, S. W. Bremer, K. J. Ye, W. Xu, J. Xu, Y. Sun, G. S. Wu, S. Savasan, S. A. Krawetz, et al.
Mitotic Cell Death by Chromosome Fragmentation
Cancer Res., August 15, 2007; 67(16): 7686 - 7694.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. L. Schmit and N. Ahmad
Regulation of mitosis via mitotic kinases: new opportunities for cancer management
Mol. Cancer Ther., July 1, 2007; 6(7): 1920 - 1931.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. A. Fecher, S. D. Cummings, M. J. Keefe, and R. M. Alani
Toward a Molecular Classification of Melanoma
J. Clin. Oncol., April 20, 2007; 25(12): 1606 - 1620.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
S. M. Wiseman, H. Masoudi, P. Niblock, D. Turbin, A. Rajput, J. Hay, S. Bugis, D. Filipenko, D. Huntsman, and B. Gilks
Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment
Ann. Surg. Oncol., February 1, 2007; 14(2): 719 - 729.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Surowiak, V. Materna, I. Kaplenko, M. Spaczynski, B. Dolinska-Krajewska, E. Gebarowska, M. Dietel, M. Zabel, and H. Lage
ABCC2 (MRP2, cMOAT) Can Be Localized in the Nuclear Membrane of Ovarian Carcinomas and Correlates with Resistance to Cisplatin and Clinical Outcome
Clin. Cancer Res., December 1, 2006; 12(23): 7149 - 7158.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. Perrone, S. Suardi, E. Pastore, P. Casieri, M. Orsenigo, S. Caramuta, G. Dagrada, M. Losa, L. Licitra, P. Bossi, et al.
Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma.
Clin. Cancer Res., November 15, 2006; 12(22): 6643 - 6651.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Kaur, R. P. Singh, M. Gu, R. Agarwal, and C. Agarwal
Grape Seed Extract Inhibits In vitro and In vivo Growth of Human Colorectal Carcinoma Cells.
Clin. Cancer Res., October 15, 2006; 12(20): 6194 - 6202.
[Abstract] [Full Text] [PDF]


Home page
Mol Biol EvolHome page
K. Nagamune and L. D. Sibley
Comparative Genomic and Phylogenetic Analyses of Calcium ATPases and Calcium-Regulated Proteins in the Apicomplexa
Mol. Biol. Evol., August 1, 2006; 23(8): 1613 - 1627.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online